(RTTNews) – Dechra Pharmaceuticals PLC (DPH.L) announced on Tuesday that it has entered into an agreement with Anivive Lifesciences, Inc. to acquire the global rights to verdinexor, a new treatment for all forms and stages of canine lymphoma in dogs.
Under the terms of the agreement, Dechra will purchase the worldwide rights to the product and a first right of refusal for other species as well as the -Laverdia brand.
Dechra said it will acquire global marketing rights, intellectual property rights, marketing authorizations (when granted) and associated regulatory documentation, supply contracts with third parties regarding raw material and manufacturing of the finished product. No other assets are transferred to Dechra.
The product, currently sold as LAVERDIA-CA1 in the United States, is a novel oral selective nuclear export inhibitor or SINE drug and the first oral tablet for canine lymphoma.
The drug was conditionally approved by the FDA Center for Veterinary Medicine on January 11, 2021.
Sales of the product in the United States began under conditional approval in July 2021. Full dossier submissions are planned for the United States, United Kingdom, EU, Brazil, Australia, Japan and the United States. Canada.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
